Adverse Events Following Immunization During Mass Vaccination Campaigns at First Introduction of a Meningococcal A Conjugate Vaccine in Burkina Faso, 2010

MenAfriVac™ is a new meningococcal A conjugate vaccine developed to prevent meningitis outbreaks in Africa. It was first introduced during the last quarter of 2010 in three West African countries. The authors of this article, published in Vaccine, report on the monitoring of adverse events following immunization (AEFI) in Burkina Faso where more than 11 million people aged 1 to 29 years were vaccinated. The monitoring of AEFI of MenAfriVac™ in Burkina Faso did not suggest special concern regarding the vaccine safety. However, reported possible hypersensitivity reactions to vaccine components would require further review to rule out any anaphylactic reaction. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Ouandaogo CR, Yaméogo TM, Diomandé FVK, et al.

Published: 2012

  • Visit web page (English)

    (Located at www.sciencedirect.com)

    Citation: Ouandaogo CRYaméogo TMDiomandé FV, et al. Adverse Events Following Immunization During Mass Vaccination Campaigns at First Introduction of a Meningococcal A Conjugate Vaccine in Burkina Faso, 2010. Vaccine. 2012;30(S2):B46–B51.